Literature DB >> 22705142

Hearing preservation after LINAC radiosurgery and LINAC radiotherapy for vestibular schwannoma.

Brendan M Fong1, Patrick Pezeshkian, Daniel T Nagasawa, Antonio De Salles, Quinton Gopen, Isaac Yang.   

Abstract

Linear accelerators (LINAC) can deliver both radiosurgery and fractionated radiotherapy. In this systematic analysis, we compare hearing preservation in patients with vestibular schwannomas (VS) treated with either LINAC-based radiotherapy (SRT) or LINAC-based radiosurgery (SRS), with an emphasis on the prognostic implications of tumor size and patient age. A total of 400 patients met our criteria for LINAC SRS, with an average hearing preservation rate of 66.3%. Patients with smaller tumors (<3.0 cm(3)) treated with SRS had similar hearing preservation rates to those with larger tumors. However, younger patients (<55 years) demonstrated improved hearing preservation compared to older patients (≥55 years). When comparing LINAC SRS to LINAC SRT directly, hearing preservation was similar in patients with smaller tumors. However, patients with larger tumors (≥3.0cm(3)) who received SRT had higher hearing preservation rates than those who received SRS. A total of 629 patients met our criteria for LINAC SRT, with an average hearing preservation rate of 75.3%. Patients with larger tumors who received SRT had better hearing outcomes than those with smaller tumors, while there was no significant difference in hearing preservation in younger patients compared to older patients. When comparing LINAC SRS to LINAC SRT directly, younger patients had similar hearing preservation rates. However, older patients who received SRT had improved hearing preservation compared to those who received SRS. In a direct comparison of average hearing preservation, patients who received SRT had higher hearing preservation rates than those who underwent SRS. Prospective studies will be needed to further characterize radiation dose and other variables.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22705142     DOI: 10.1016/j.jocn.2012.01.015

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  12 in total

1.  Hearing Preservation in Stereotactic Radiosurgery for Vestibular Schwannoma.

Authors:  Anthony M Tolisano; Jacob B Hunter
Journal:  J Neurol Surg B Skull Base       Date:  2019-01-10

2.  An audiological analysis of stereotactic radiation strategies to preserve hearing in patients with vestibular schwannomas.

Authors:  Shoshana Movsas; Michael Hefferly; Benjamin Movsas; Valeriy Shafiro
Journal:  J Radiosurg SBRT       Date:  2014

3.  Five-year outcomes following hypofractionated stereotactic radiotherapy delivered in five fractions for acoustic neuromas: the mean cochlear dose may impact hearing preservation.

Authors:  Zhiping Chen; Keiichi Takehana; Takashi Mizowaki; Megumi Uto; Kengo Ogura; Katsuyuki Sakanaka; Yoshiki Arakawa; Yohei Mineharu; Yuki Miyabe; Nobutaka Mukumoto; Susumu Miyamoto; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2018-03-19       Impact factor: 3.402

4.  Longitudinal Radiographic Outcomes of Vestibular Schwannoma in Single and Fractionated Stereotactic Radiosurgery: A Retrospective Cohort Study.

Authors:  Mohamed H Khattab; Neil B Newman; David M Wharton; Alexander D Sherry; Guozhen Luo; Nauman F Manzoor; Alejandro Rivas; L Taylor Davis; Lola B Chambless; Albert Attia; Anthony J Cmelak
Journal:  J Neurol Surg B Skull Base       Date:  2019-06-12

5.  LINAC-based stereotactic radiosurgery versus hypofractionated stereotactic radiotherapy delivered in 3 or 5 fractions for vestibular schwannomas: comparative assessment from a single institution.

Authors:  Linn Söderlund Diaz; Andreas Hallqvist
Journal:  J Neurooncol       Date:  2020-02-08       Impact factor: 4.130

6.  Fractionated vs. single-fraction stereotactic radiotherapy in patients with vestibular schwannoma : Hearing preservation and patients' self-reported outcome based on an established questionnaire.

Authors:  Kerstin A Kessel; Hanna Fischer; Marco M E Vogel; Markus Oechsner; Henning Bier; Bernhard Meyer; Stephanie E Combs
Journal:  Strahlenther Onkol       Date:  2016-11-01       Impact factor: 3.621

7.  Impact of Cochlear Dose on Hearing Preservation following Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy for the Treatment of Vestibular Schwannoma.

Authors:  Lawrance K Chung; Nolan Ung; John P Sheppard; Thien Nguyen; Carlito Lagman; Winward Choy; Stephen Tenn; Nader Pouratian; Percy Lee; Tania Kaprealian; Michael Selch; Antonio De Salles; Quinton Gopen; Isaac Yang
Journal:  J Neurol Surg B Skull Base       Date:  2017-11-10

8.  Long-Term Hearing Outcomes Following Stereotactic Radiosurgery in Vestibular Schwannoma Patients-A Retrospective Cohort Study.

Authors:  Peter L Santa Maria; Yangyang Shi; Richard K Gurgel; C Eduardo Corrales; Scott G Soltys; Chloe Santa Maria; Kevin Murray; Steven D Chang; Nikolas H Blevins; Iris C Gibbs; Robert K Jackler
Journal:  Neurosurgery       Date:  2019-10-01       Impact factor: 4.654

9.  Patterns of stereotactic radiotherapy utilization and fractionation for acoustic neuroma in the United States.

Authors:  Baho Sidiqi; Niki Sheth; Anna Lee; Joseph Safdieh; David Schreiber
Journal:  J Radiosurg SBRT       Date:  2018

Review 10.  Stereotactic Radiosurgery for Vestibular Schwannomas: Tumor Control Probability Analyses and Recommended Reporting Standards.

Authors:  Scott G Soltys; Michael T Milano; Jinyu Xue; Wolfgang A Tomé; Ellen Yorke; Jason Sheehan; George X Ding; John P Kirkpatrick; Lijun Ma; Arjun Sahgal; Timothy Solberg; John Adler; Jimm Grimm; Issam El Naqa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-12-26       Impact factor: 8.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.